With 1.44 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.71 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $94.75 whereas the lowest price it dropped to was $93.085. The 52-week range on ALC shows that it touched its highest point at $101.10 and its lowest point at $77.54 during that stretch. It currently has a 1-year price target of $107.05. With its current market cap of 46.83 billion, ALC has annualized dividend of $0.26 while the current yield stands at 0.28%. ALC paid its most recent dividend on 1715644800, while the ex-dividend date for that was 1747094400. Beta for the stock currently stands at 1.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALC was up-trending over the past week, with a rise of 2.86%, but this was up by 2.03% over a month. Three-month performance surged to 6.25% while six-month performance rose 0.36%. The stock gained 17.45% in the past year, while it has gained 11.53% so far this year. A look at the trailing 12-month EPS for ALC yields 2.05 with Next year EPS estimates of 3.74. For the next quarter, that number is 0.75. This implies an EPS growth rate of 6.15% for this year and 15.51% for next year.
Float and Shares Shorts:
At present, 494.60 million ALC shares are outstanding with a float of 489.33 million shares on hand for trading. On 2025-03-31, short shares totaled 2.77 million, which was 55.99999999999999 higher than short shares on 1740700800. In addition to Mr. David J. Endicott as the firm’s CEO & Director, Mr. Timothy C. Stonesifer serves as its Senior VP & CFO.
Institutional Ownership:
Through their ownership of 0.75339997 of ALC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, ALC reported revenue of $2502000000.0 and operating income of $395000000.0. The EBITDA in the recently reported quarter was $397000000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALC since 13 analysts follow the stock currently. There are 12 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALC analysts setting a high price target of 120.0 and a low target of 86.0, the average target price over the next 12 months is 106.652. Based on these targets, ALC could surge 26.74% to reach the target high and fall by -9.17% to reach the target low. Reaching the average price target will result in a growth of 12.64% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $3.00207 being high and $2.97244 being low. For ALC, this leads to a yearly average estimate of $2.99219. Based on analyst estimates, the high estimate for the next quarter is $0.82 and the low estimate is $0.75. The average estimate for the next quarter is thus $0.78.
